LENZHealthcare · BiotechnologyThe 7 Wall Street analysts covering LENZ Therapeutics, Inc. hold a median 12-month price target of $10 — +113.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores LENZ Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (72): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LENZ, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +113.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Piper Sandler | Maintains | Neutral | $12 → $7.00 |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $38 |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2026 | Citigroup | Maintains | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 21 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 20 Oct 2025 | Raymond James | Reiterates | Outperform | — |
| 10 Oct 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 Aug 2025 | Citigroup | Maintains | Buy | — |
| 1 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2025 | Citigroup | Maintains | Buy | — |
| 31 July 2025 | Raymond James | Maintains | Outperform | — |
| 28 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Apr 2025 | Piper Sandler | Maintains | Overweight | — |
| 20 Mar 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LENZ appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 20% of US stocks
Cheaper than 82% of US stocks
Cheaper than 58% of US stocks
Higher than 51% of US stocks
Higher than 55% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 19% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LENZ Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of LENZ Therapeutics, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion of the company's second-quarter performance and outlook.
Why it matters — LENZ watchers would use the earnings call transcript to hear management's own commentary on quarterly results and guidance directly from the company.
LENZ Therapeutics reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and increased prescription activity following the July rollout of national TV advertising and a telehealth access option.
Why it matters — The update offers LENZ watchers a closer look at early commercial traction for its product VIZZ, including revenue figures and prescription trends.
LENZ Therapeutics reported a quarterly loss of $1.02 per share for Q2, which was narrower than the Zacks Consensus Estimate of a loss of $1.21, but wider than the year-ago loss of $0.53 per share. The company beat revenue estimates for the quarter.
Why it matters — The loss came in better than analysts expected even though it widened from the prior-year period, giving LENZ watchers a data point on the company's quarterly performance versus consensus.
LENZ Therapeutics reported financial results for the second quarter ended June 30, 2026, including total revenue of $5.5 million from VIZZ product sales and global license agreements. The company also noted strong patient persistence, with over 60% of patients in its dominant ePharmacy channel purchasing multiple monthly packs since launch, and reported that VIZZ prescription growth accelerated with the launch of its telehealth channel in July 2026.
Why it matters — The update provides LENZ watchers with a first look at the commercial performance and revenue from VIZZ since launch, along with signals on patient persistence and prescription growth.
LENZ Therapeutics announced it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights.
Why it matters — The upcoming webcast will give LENZ watchers the company's second quarter financial results and an update on its recent corporate activities.
The 7 Wall Street analysts covering LENZ Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering LENZ Therapeutics, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENZ Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, LENZ Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +113.7% from the last close, and Ticker Nerd's factor model ranks LENZ Therapeutics, Inc. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LENZ Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LENZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $60 over the next 12 months.
LENZ Therapeutics, Inc. is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of LENZ Therapeutics, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion of the company's second-quarter performance and outlook.
LENZ Therapeutics, Inc. is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. This innovative once-daily eye drop aims to restore near vision, addressing the gradual loss of focusing ability that affects adults typically over age 45, offering a pharmaceutical alternative to reading glasses for a broad patient population. The company is actively commercializing VIZZ™ in the United States while establishing licensing partnerships internationally to expand global access. Headquartered in Solana Beach, California, LENZ Therapeutics operates in the ophthalmic pharmaceuticals sector, supported by a leadership team with deep expertise in biopharmaceutical development, clinical operations, regulatory affairs, manufacturing, marketing, sales, and commercial strategy. Their novel product targets the presbyopia market, providing a targeted solution to improve vision clarity and quality of life for millions impacted by this common age-related condition.
CEO Mr. Evert B. Schimmelpennink · 152 employees · United States · https://www.lenz-tx.com